期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

马来酸替加色罗片健康人体药代动力学试验 被引量：1

Pharmacokinetic studies of Tegaserod Maleate Tablet in healthy volunteers
下载PDF
导出
摘要 目的进行健康志愿者马来酸替加色罗片单剂和多剂给药的药代动力学研究.方法采用LC-MS法测定替加色罗经时血浓度,计算替加色罗主要药代动力学参数,了解替加色罗口服给药在人体分布、消除、蓄积规律.结果及结论采用LC-MS方法测定替加色罗血浓度,灵敏度高,回收率和日内日间变异符合生物样本研究要求. OBJECTIVE Pharmacokinetic characteristics of the single dose and muhidose of Tegaserol were evaluated in Chinese healthy volunteers METHODS The concerntrations of Tegaserod in plasma were determined by LC-MS method and its pharmacokinetic parameters were calculated, RESULTS and CONCLUSION The LC- MS method is sensitive and suitable to Tegaserol human pharmacokinetic studies. The recovery rate and variations of within day and between day both conformed to the biological sample research requirement.
作者 司继刚 王本杰 郭瑞臣
机构地区 山东大学药学院 淄博市中心医院 山东大学齐鲁医院临床药理研究所
出处 《齐鲁药事》 2006年第6期365-367,共3页 qilu pharmaceutical affairs
关键词 马来酸替加色罗片 药代动力学 液相色谱-质谱联用仪 Tegaserod maleate pharmacokinetics LC-MS
分类号 R969.1 [医药卫生—药理学]
  • 相关文献

参考文献3

二级参考文献11

  • 1JAIN A, TOUGAS G. Tegaserod-a novel therapeutic agent for irritable bowel syndrome[J ]. Today' s Ther Trends, 2001, 19 (2) : 105-116.
  • 2CAMILLER.I M. Review article: tegaserod[J]. Aliment Pharmacol Ther, 2001, 15(3): 277-289.
  • 3APPEL S, KUMLE A, HUBERT M, et al. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist [ J ]. J Clin Pharmacol, 1997, 37 (3) :229-237.
  • 4Scarpignato C,Pelosini I.Management of irritable bowel syndrome:novel approaches to the pharmacology of gut motility[J].Can J Gastroenterol,1999,13(Suppl A)∶S50A-S65A.
  • 5Callahan MJ.Irritable bowel syndrome neuropharmacology.A review of approved and investigational compounds[J].J Clin Gastroenterol,2002,35(1 Suppl)∶S58-S67.
  • 6Lacy BE,Yu S.Tegaserod:a new 5-HT4 agonist[J].J Clin Gastroenterol,2002,34(1)∶27-33.
  • 7Appel-Dingemanse S.Clinical pharmacokinetics of tegaserod,a serotonin 5-HT(4) receptor partial agonist with promotile activity[J].Clin Pharmacokinet,2002,41(13)∶1021-1042.
  • 8Fidelholtz J,Smith W,Rawls J,et al.Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms[J].Am J Gastroenterol,2002,97(5)∶1176-1181.
  • 9Prather CM,Camilleri M,Zinsmeister AR,et al.Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome[J].Gastroenterology,2000,118(3)∶463-468.
  • 10Novick J,Miner P,Krause R,et al.A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation[J].Aliment Pharmacol Ther,2002,16(11)∶1877-1888.

共引文献6

同被引文献6

  • 1司继刚,郭瑞臣,王本杰.马来酸替加色罗胶囊与其片剂的人体生物等效性[J].中国临床药学杂志,2006,15(2):96-99. 被引量：6
  • 2文爱东,毕琳琳,贾艳艳,周敏,吴寅,王志睿.马来酸替加色罗分散片的人体生物等效性研究[J].中国药房,2007,18(8):592-594. 被引量：1
  • 3Viekers AE, Zollinger M, Dannecker R. et al. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions[J]. Drug Metab Disp, 2001 ;29:1269 - 1276.
  • 4Appel S, Kumle A, Hubert M, et al. First pharmacokineticpharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist [ J]. J Clin Pharmacol, 1997;37:229 - 237.
  • 5Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity [J]. Clin Pharmacokinet, 21302;41 : 1021 - 1042.
  • 6张乐之,魏斌,周红.马来酸替加色罗[J].中国新药杂志,2002,11(12):968-969. 被引量：3

引证文献1

二级引证文献1

齐鲁药事
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部